Held, Peter

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet

Heart Failure Treatment and ManagementRenin-Angiotensin System Studies

Cited by 2,994

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet

Heart Failure Treatment and ManagementRenin-Angiotensin System Studies

Cited by 2,604

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

Granger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., Östergren, J., Pfeffer, M. A., & Swedberg, K. (2003) · The Lancet

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 1,686

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

Hiatt, W. R., Fowkes, F. G. R., Heizer, G., Berger, J. S., Baumgartner, I., Held, P., Katona, B. G., Mahaffey, K. W., Norgren, L., Jones, W. S., et al. (2017) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 636

Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial

Berger, J. S., Katona, B. G., Jones, W. S., Patel, M. R., Norgren, L., Baumgartner, I., Blomster, J., Mahaffey, K. W., Held, P., Millegård, M., et al. (2016) · American Heart Journal

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 47